Teva Exits Japanese Generics With Plan To Sell Local Business

Firm Registers Impairment Charge Of Almost $600m As Unit Is Classified As Held-For-Sale

09 May 2024

Teva is putting its Japanese generics business up for sale, in an exit from the country’s generics market that has led the Israeli firm to register a substantial impairment charge in Q1.

Yen symbol in front of doorway with red background — Teva is facing an exit from its Japanese generics business • Source: Shutterstock

Teva is exiting the Japanese generics market, putting its local generics business up for sale in a process that the Israeli generics giant expects to close within the next 12 months.

Quietly announcing the decision during the firm’s first-quarter results call, chief financial officer Eli Kalif explained that “as part of...